Cyxone receives Intention to Grant from the European Patent Office for the divisional patent of T20K
Cyxone (publ), a biotech company in autoimmune diseases, is pleased to announce that the European Patent Office has issued an intention to grant communication for EP-Divisional Patent Application 18 172 126.7 entitled Cyclotides as immunosuppressive agents. The application covers the protection of the drug candidate T20K that Cyxone licenses from the Medical University of Vienna and the University of Freiburg.The intention to grant is a formal communication from the patent authority in which it indicates that the patent application has reached the status where it is allowed for issuance as